alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › immunotherapies

immunotherapies

4 studies tagged immunotherapies, dated 2007-09-20 to 2026-03-30. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Amyloid-Beta Immunotherapies for Alzheimer's Disease: Current Progress 2026-03-30
  2. Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions 2025-07-21
  3. Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies 2015-04-16

Studies

4 studies carry this tag.

Date range

2007 to 2026

Top journals

  • Current Alzheimer research 1
  • Nature reviews. Neurology 1
  • Scientific reports 1
  • Vision research 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Amyloid-Beta Immunotherapies for Alzheimer's Disease: Current Progress

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Current Alzheimer research 2026-03-30 Treatments

    Alzheimer's Disease (AD) is a major global challenge and the most common cause of dementia worldwide.

  2. Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Nature reviews. Neurology 2025-07-21 Treatments

    The treatment of Alzheimer disease (AD) has crossed a pivotal threshold, marked by the landmark approvals of the first-ever disease-modifying therapies.

  3. Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Scientific reports 2015-04-16 Treatments

    Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-β (Aβ) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals.

  4. Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Vision research 2007-09-20 Treatments

    Age-related macular degeneration (AMD) is a late-onset, neurodegenerative retinal disease that shares several clinical and pathological features with Alzheimer's disease (AD) including extracellular deposits containing amyloid-beta (Abeta) peptides.

All topic tags with their study counts